Related Experiment Video
Updated: May 13, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Adaptive designs for dual-agent phase I dose-escalation studies.
Jennifer A Harrington1, Graham M Wheeler, Michael J Sweeting
1Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. jenny.harrington@cruk.cam.ac.uk
Combining anticancer agents is key for curative cancer treatment. New adaptive designs can better explore drug interactions in dual-agent phase I trials, but require collaboration for successful implementation.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Combination anticancer therapy is crucial for curative cancer treatment.
- Phase I trials aim to determine safe drug doses and schedules for further testing.
- Current methods for combination trials may not fully capture drug interactions.
Purpose of the Study:
- To review methods for dual-agent phase I trials.
- To discuss challenges and opportunities in these trials.
- To highlight the benefits of adaptive, model-based designs.
Main Methods:
- Review of existing literature on phase I combination trials.
- Discussion of adaptive, model-based trial designs.
- Examples of successful adaptive design implementation.
Main Results:
- Current methods may limit the exploration of drug interactions.
- Adaptive designs offer improved approaches for dual-agent trials.
- Successful implementation of adaptive designs has been demonstrated.
Conclusions:
- Improving dual-agent phase I trials requires enhanced designs.
- Adaptive, model-based designs can better explore drug interactions.
- Collaboration between statisticians and clinicians is vital for adopting new designs.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Dosage Regimens: Designs and Approaches
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Dosage Regimen: Individualization
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs